Cabaletta Bio Past Earnings Performance
Past criteria checks 0/6
Cabaletta Bio's earnings have been declining at an average annual rate of -25.7%, while the Biotechs industry saw earnings growing at 15.5% annually.
Key information
-25.7%
Earnings growth rate
49.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -34.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
May 22
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Jan 31Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Dec 28Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Sep 12Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Jun 04Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Oct 20We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Jul 07Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Mar 24We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 09We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Aug 05Cabaletta Bio EPS beats by $0.08
May 03Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Apr 12What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?
Feb 19
Chardan Capital initiates Cabaletta Bio with Buy rating
Jan 08We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 28Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder
Dec 09Cabaletta Bio +5% on Q3 results, pipeline update
Nov 10Revenue & Expenses Breakdown
How Cabaletta Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -77 | 21 | 65 |
| 31 Dec 23 | 0 | -68 | 19 | 55 |
| 30 Sep 23 | 0 | -62 | 17 | 50 |
| 30 Jun 23 | 0 | -57 | 16 | 45 |
| 31 Mar 23 | 0 | -56 | 16 | 43 |
| 31 Dec 22 | 0 | -53 | 15 | 39 |
| 30 Sep 22 | 0 | -51 | 15 | 37 |
| 30 Jun 22 | 0 | -51 | 15 | 37 |
| 31 Mar 22 | 0 | -50 | 14 | 35 |
| 31 Dec 21 | 0 | -46 | 14 | 32 |
| 30 Sep 21 | 0 | -42 | 14 | 28 |
| 30 Jun 21 | 0 | -39 | 13 | 26 |
| 31 Mar 21 | 0 | -36 | 13 | 23 |
| 31 Dec 20 | 0 | -33 | 13 | 21 |
| 30 Sep 20 | 0 | -29 | 12 | 18 |
| 30 Jun 20 | 0 | -26 | 11 | 16 |
| 31 Mar 20 | 0 | -21 | 9 | 13 |
| 31 Dec 19 | 0 | -22 | 7 | 11 |
| 30 Sep 19 | 0 | -19 | 5 | 10 |
| 30 Jun 19 | 0 | -23 | 4 | 9 |
| 31 Mar 19 | 0 | -21 | 3 | 7 |
| 31 Dec 18 | 0 | -12 | 2 | 4 |
Quality Earnings: CABA is currently unprofitable.
Growing Profit Margin: CABA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CABA is unprofitable, and losses have increased over the past 5 years at a rate of 25.7% per year.
Accelerating Growth: Unable to compare CABA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CABA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: CABA has a negative Return on Equity (-34.67%), as it is currently unprofitable.